Premium
Spontaneous resolution of Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis
Author(s) -
Belyea Brian,
Hinson Ashley,
Moran Cassandra,
Hwang Eugene,
Heath Jessica,
Barfield Raymond
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22618
Subject(s) - hemophagocytic lymphohistiocytosis , medicine , epstein–barr virus , virology , virus , resolution (logic) , pathology , disease , artificial intelligence , computer science
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a reactive, proliferative disorder of the immune system resulting in lymphohistiocytic proliferation, hemophagocytosis, and cytokine dysregulation. The most common infectious trigger in sHLH is Epstein–Barr virus (EBV‐HLH). Current treatment protocols for EBV‐HLH have a cure rate of approximately 75%; however, there are significant toxicities associated with these therapies. We present two patients with EBV‐HLH who experienced spontaneous resolution of their disease prior to the initiation of therapy, suggesting there may be a subgroup of patients with EBV‐HLH who do well with conservative management and can avoid potentially toxic therapies. Pediatr Blood Cancer. 2010;55:754–756. © 2010 Wiley‐Liss, Inc.